Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07608432 · ClinicalTrials.gov registry record · Phase 3
Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)
A Phase 3 study, sponsored by Dyne Therapeutics.
- Recruiting
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT07608432: Recruiting Phase 3 study, sponsored by Dyne Therapeutics.
NCT07608432 is a Phase 3 study that is actively recruiting participants, run by Dyne Therapeutics. The registered enrollment target is 90 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07608432, a Phase 3 study, is actively recruiting participants, sponsored by Dyne Therapeutics.
- RECRUITING
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
Interventions
- DRUG Placebo
- DRUG Zeleciment Rostudirsen (DYNE-251)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-06 |
| Est. Completion | 2032-10 |
| Phase | Phase 3 |
What NCT07608432 shows while recruiting
NCT07608432 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 90 participants, a relatively small participant target, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (88% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT07608432 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT07608432 about?
NCT07608432 is a clinical study titled "Efficacy, Safety, and Tolerability of Zeleciment Rostudirsen (DYNE-251) Administered Intravenously Every 4 Weeks in Ambulatory Participants With Duchenne Muscular Dystrophy (FORZETTO)". The purpose of the study is to assess the efficacy, safety, and tolerability of zeleciment rostudirsen (DYNE-251) administered intravenously (IV) every 4 weeks to ambulatory Duchenne muscular dystrophy (DMD) participants, 4 to 18 years of age, with dystrophin mutations amenable to exon 51 skipping.
What is the current status of trial NCT07608432?
This trial is currently recruiting. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2026-06. Estimated completion is 2032-10.
What interventions are being tested in trial NCT07608432?
The interventions under investigation include: Placebo (DRUG), Zeleciment Rostudirsen (DYNE-251) (DRUG).
Who is sponsoring clinical trial NCT07608432?
This trial is sponsored by Dyne Therapeutics, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07608432's enrollment target sits among peer trials
90 1724th of 2000 higher than 263 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02521311 · 90 participants · Phase 2
Assessment of Clemastine Fumarate as a Remyelinating Agent in Acute Optic Neuritis (ReCOVER)
- NCT02939573 · 90 participants · Phase 2
A Randomized Multicenter Study for Isolated Skin Vasculitis
- NCT03128879 · 90 participants · Phase 2
Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL
- NCT03184038 · 90 participants · NA
Neurocognition in Patients With Multiple Brain Metastases Treated With Radiosurgery
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia